Positively Aware
VerifiedMagazine
Positively Aware (PA) is a not-for-profit HIV/AIDS treatment journal published by Test Positive Aware Network (TPAN), a 501c3, not-for-profit AIDS Service Organization (ASO) in Chicago. TPAN, now in its 25th year, is one of Chicago’s most respected and trusted ASO’s. No other national HIV/AIDS publication is produced by a notfor- profit AIDS Service Organization.
Source
Actions
Media Outlet details
| Scope | National |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Bimonthly |
Recent Articles
Search ArticlesGLAAD's new HIV stigma report points to gaps in knowledge-and visibility
2026 State of HIV Stigma report, based on a 2025 online survey of 2,500 U.S. adults plus nine focus groups. Respondents recognized that HIV is stigmatized, but many of them didn't have accurate information about the subject-they expressed disbelief about "Undetectable = Untransmittable" and said they felt discomfort around people living with the virus.
GLAAD's new HIV stigma report points to gaps in knowledge-and visibility
2026 State of HIV Stigma report, based on a 2025 online survey of 2,500 U.S. adults plus nine focus groups. Respondents recognized that HIV is stigmatized, but many of them didn't have accurate information about the subject-they expressed disbelief about "Undetectable = Untransmittable" and said they felt discomfort around people living with the virus.
GLAAD's new HIV stigma report points to gaps in knowledge-and visibility
2026 State of HIV Stigma report, based on a 2025 online survey of 2,500 U.S. adults plus nine focus groups. Respondents recognized that HIV is stigmatized, but many of them didn't have accurate information about the subject-they expressed disbelief about "Undetectable = Untransmittable" and said they felt discomfort around people living with the virus.
FDA approves a new two-drug combo for people on complex HIV treatment
phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials , which showed that the once-daily pill maintained similar virologic suppression as Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg). Bixlenvo's two-drug combo was generally well tolerated, with no significant or new safety concerns. Detailed ARTISTRY-1 results were published in , and ARTISTRY-2 results were published in .
FDA approves a new two-drug combo for people on complex HIV treatment
phase 3 ARTISTRY-1 and ARTISTRY-2 clinical trials , which showed that the once-daily pill maintained similar virologic suppression as Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg). Bixlenvo's two-drug combo was generally well tolerated, with no significant or new safety concerns. Detailed ARTISTRY-1 results were published in , and ARTISTRY-2 results were published in .